This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Angeletti, S., Corleto, V.D., and Schiallachi, O. (1998). Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42, 792–794.
Anthony, L., Johnson, D., and Hande, K. (1993). Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32, 217–223.
Anthony, L.B., Skyr, Y., Wim, S.D., and Oates, J.A. (1996). Octreotide acelate (OA) in the management of malignant carcinoid syndrome (CS). Ann Oncol 7(suppl 5), 47 (abs 219P).
Arnold, R., Trautmann, M.E., and Creutzfeldt, W. (1996). Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38, 430–438.
Bauer, W., Briner, U., and Doepfner W. (1982). A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31, 1133–1140.
Bergström, M., Eriksson, B., and Öberg K. (1996). In vivo demonstration of enzyme activity in endocrine pancreatic tumors-decarboxylation of 11C-dopa to 11C-dopamine. J Nucl med 36, 32–37.
Buscail, L., Esteve, J.P., and Saint-Laurent, N. (1995). Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci 92, 1580–1584.
Carrasco, C.H., Chuang, V., and Wallace, S. (1983). Apudoma metastatic to the liver: Treatment by hepatic artery embolization. Radiology 149, 79–83.
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., and the ITMO Association (1996). Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 77, 402–408.
Eckhauser, F.E., Cheung, P.S., and Vinik, A.I. (1986). Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 100, 978.
Eriksson, B., Arnberg, H., and Lindgren, P.G. (1990). Neuroendocrine pancreatic tumors: Clinical presentation, biochemical and histopathological tumors: Clinical presentation, biochemical and histopathological findings in 84 patients. J Int Med 228, 103–113.
Eriksson, B., Janson ET, and Bax, N.D.S. (1996). The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors. Digestion 57, 77–80.
Eriksson, B., Renstrup, J., Imam, H., and Öberg, K. (1997). High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 8, 1041–1044.
Eriksson, B., and Öberg, K. (1999). Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors. Future outlook. Ann Oncol 10(Suppl 2), S1–8.
Faiss, S., and Wiedenmann, B. (1997). Dose-dependent and antiprolifcrativc effects of somatostatin. J Endocrinol Invest 20, 68–70.
Fajans, S.S., and Vinik, A.I. (1989). Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 18, 45.
Feldman, J.M. (1987). Carcinoid tumors and syndrome. Semin Oncol 14, 237.
Frank, M., Klose, K.J., Wied, M., Ishaque, N., Schade-Brittinger C., and Arnold, R. (1999). Combination therapy with octreotide and α-interferon: Effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94, 1382–1387.
Fröhlich, J.C., Bloomgarden, Z.T., and Oates, J.A. (1978). The carcinoid flush: Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299, 1055–1057.
Gorden, P., Comi, R.J., Maton, P.N., and Go V.L.W. (1989). Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110, 35–50.
Harris, A., Kokoris, S., and Ezzat, S. (1995). Continuous versus intermittent sub-cutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol 35, 59–71.
Harris, A., and Redfern, J.S. (1995). Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data. Aliment of published dose-titration data. Aliment Pharmacol Ther 9, 387–394.
Heron, I., Thomas, F., and Dero, M. (1993). Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BlM-23014 in patients with acromegaly. J clin Endocrinol Metabol 76, 721–727.
Hoefnagel, C.A., den Hartog Jager, F.C., and Taal, E.G. (1987). The role of 125I-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13, 187.
Hofland, L.J., Koelsveld, and Waaijers, M. (1994). Relative potencies of the somato-statin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultures human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinol 134, 301–306.
Imam, H., Eriksson, B., and Lukinius A. (1997). Induction of apoptosis in neuro-endocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 36, 607–614.
Janson, E.T., Ahlström, H., Andersson, T., and Öberg, K (1992). Octreotide and interferon-α: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 28A, 1647–1650.
Jensen, R.T. (1983). Zollinger-Ellison syndrome: Current concepts and management. Ann Int Med 98, 59–75.
Jockenhovel, S., Lederbogen S., and Olbricht, T. (1994). The long-acting somatostatin analogue: Symptomatic and peptide response. Gut 26, 127–133.
Joensuu, H., Kätkä, K. and Kujari, H. (1992). Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 126, 184–185.
Krejs, G.J., Ocri, L., and Conlon, M. (1979). Somatostatinoma syndrome (biochemical, morphological, and clinical features). N Engl J Med 301, 285.
Krenning, E.P., Kwekkeboom, D.J., and Bakker, W.H. (1993). Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1) and (123Tyr3)-octreotide. The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20, 716–731.
Kvols, L.K., Marsh, H.M., and Moertel, C.G. (1985). Rapid reversal of carcinoid crisis with a somatostatin analouge. N Engl J Med 313, 1229–1230.
Kvols, L.K., Moertel, C.G., and O’Connell M.J. (1986). Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315, 663–666.
Kvols, L.K., and Reubi, J.C. (1993). Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 32:2, 197–201.
Lamberts, S.W.J., Krenning, E.P., and Reubi, J.C. (1991). The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 12, 450–482.
Lancranjan, I., Brims, C., and Grass, P. (1995). Sandostatin-LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 44, 18–26.
Larsson, C., Skogseid B., and Öberg, K. (1988). Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332, 85–87.
Long, R.G., Bryant, M.G., and Mitchell, S.J. (1981). Clinicopathological study of pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestinal polypeptide (VIPomas). Br J Med J 282, 1767.
Makridis, C., Öberg, K., and Juhlin, C. (1990). Surgical tretment of midgut carcinoid tumors. World J Surg 14, 377.
Maton, P.N., Gardner, J.D., and Jensen, R.T. (1989). Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34, 285–291.
Moertel, C.G., Johnson, C.M., and McKusick, M.A. (1994). The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 120, 302–309.
Nagy, A., Schally, A.V., Halmos, G., Armatis, P., Cai, R.Z., and Csernus, V. (1986). Synthesis and biological evaluation of cytotoxic analogues of somatostatin containing doxorubicin and its potent derivative 2-pyrrolinodoxorubicin. Br J Surg 83, 456–460.
Norheim, I., Öberg, K., and Theodorsson-Norheim, E. (1987). Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206, 115–125.
Otte, A., Mueller-brand, J., and Dellas, S. (1998), Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 351, 417–418.
Patel, Y.C. (1999). Somatostatin and its receptor family. Frontiers in Neuroendo-crinology 20, 157–198.
Radulovic, S., Nagy, A., Szoke, B., and Schally, A. (1992). Cytotoxic analogue of somatostatin containing methotrexate inhibits growth of MIA PaCA-2 human pancreatic xenografts in nude mice. Cancer lett 62, 263–271.
Reubi, J.C., Kvols, L.K., and Waser, B. (1990). Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples and islet cell carcinomas. Cancer Res 50, 5969–5977.
Ricci, S., Anonuzzo, A., Galli, L., Ferdeghini, M., Bodei, L., Orlandini, C., and Conte, P.F. (2000). Octreotide acelate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotidc. Ann Oncol 11, 1127–1130.
Rindi, G., Luinetti, O., and Cornaggia, M. (1993). Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma. A Clinicopathological study. Gastroenterol 104, 994–1006.
Rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., and Patel, Y.C., (2000). Receptors for dopamine and somatostatin: Formalin of hetero-oligomers with enhanced functional activity. Science 288, 154–157.
Rubin, J., Ajani, J., Schinner, W., Wenok, A.P., Bukowski, R., Pommier, R., Salz, L., Danona, P., and Anthony, L. (1999). Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17, 600–606.
Ruszniewski, P., Ramdani, A., and Cadiot G. (1993). Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Fur J Clin Invest 23, 296–301.
Ruszniewski, P., Ducreux, M., and Chay vialle, J.A. (1996). Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide. A prospective study in 39 patients. Gut 39, 279–283.
Saltz, L., Trochanowski, B., and Buckley, M. (1993). Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72, 244–248.
Scarpignato, C. (1995). Somatostatin analogues in the management of endocrine tumors of the pancreas. In Mignon M, Jensen RT (eds): Endocrine Tumors of the Pancreas. Basel: Karger, 385–414.
Scarpignato, C., and Pelosini, I. (2001). Somatostatin analogs for cancer treatment and diagnosis-an overview; In: Somatostatin Analogs in Cancer Management. Ed. C. Scarpignato (Karger). Chemotherapy 47(Suppl 2), 1–29.
Scherübl, H., Wiedenmann, B. and Riecken, E.O. (1994). Treatment of the carcinoid syndrome with a depot formulation of the Somatostatin analogue lanreotide. Eur J Cancer 6, 1590–1591.
Sharma, K., Patel, X.C., and Srikant, C.B. (1996). Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human Somatostatin receptor 3. Mol Endocrinol 10, 1688–1696.
Shi, W., Buchanan, K.D., Johnston, C.F., Larkin, C., Ong, Y.L., Ferguson, R., and Laird, J. (1998). The octreotide suppression test and (111In-DTPA-D-Ph1)-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to Somatostatin analogue treatment. Clin Endocrinol 48, 303–309.
Shimon, I., Taylor, J., and Weiss, M.H. (1997). Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J clin Invest 100, 2386–2392.
Skogseid, B., Eriksson, B., and Lundqvist, G. (1991). Multiple endocrine neoplasia type 1: A ten-year preospective screening study in four kindreds. J Clin Endocrinol Metab 73, 281–287.
Spread, C., Berkel, H., and Jewell L. (1994). Colon carcinoid tumors. A population-based study. Dis Colon Rectum 37, 482–491.
Stacpoole, P.W. (1981). The glucagonoma syndrome: Clinical features, diagnosis, and treatment, endocr Rev 2, 347.
Taylor, J.E., Bogden, A.E., Moreau, J.P., and Coy D.H. (1988). In vitro inhibition of human small-cell carcinoma (NCL-H69) growth by Somatostatin analogue. Biochem Biophys Res Commun 153, 81–86.
Tiensuu Janson, E., Westlin, J.E., and Eriksson, B. (1994). (111In-DTPA-D-Phe1)-Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for Somatostatin analog treatment. Eur J Endocrinol 131, 577–581.
Trendle, M.C., Moertel, C.G., and Kvols, L.K. (1997). Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumours. Cancer 79, 830–834.
Thulin, L., Samnegård, H., and Tyden, G. (1978). Efficacy of Somatostatin in a patient with carcinoid syndrome. Lancet 2, 43.
Weckbecker, G., Liu, R., Tolcsvai, L., and Bruns, C. (1992). Antiproliferative effectsof the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52, 4973–4978.
Wilander, E., Lundqvist, M., and Öberg, K. (1989). Gastrointestinal carcinoid tumours. Prog Histochem Cytochem 19, 1–85.
Williams, E.D., and Sandler, M. (1963). The classification of carcinoid tumours. The Lancet 1, 238–239.
Woltering, E.A., Watson, J.C., Alperin-Lea, C, Sharma, C., Keenan, E., Kurdzawa, D.L., and Barrie, R. (1997). Somatostatin analogues: Angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15, 77–86.
Wood S.M., Kraenzlin, M.E., Adrian, T.E., and Bloom, S.R (1985) Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide response. Gut 26, 438–444.
Wymenga, A.N.M., Eriksson, B., and Salmela, P.I. (1999). Efficacy and safety of lanreotide prolonged release in patients with gastrointestinal neuro-endocrine tumors with hormone related symptoms. J Clin Oncol 4, 1111–1117.
Wynick, D., Andersson, J.V., Williams, S.J., and Bloom, S.R. (1989). Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30, 385–388.
Öberg, K., Norheim, I., Lundqvist, G., and Wide, L. (1986). Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analouge. Scand J Gastroenterol 119, 191–192.
Öberg, K., and Eriksson, B. (1991). The role of interferons in the management of carcinoid tumors. Acta Oncol 30, 519–522.
Öberg, K. (1996). Neuroendocrine tumors. Ann Oncol 7, 453–463.
Öberg, K. (2001). Established clinical use of octreotide and lancreotide in oncology. Chemotherapy 47,(suppl 2), 40–53.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Öberg, K. (2004). Somatostatin Analogue Therapy of Neuro-Endocrine Gastro-Entero Pancreatic Tumors. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_16
Download citation
DOI: https://doi.org/10.1007/1-4020-8033-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7799-9
Online ISBN: 978-1-4020-8033-3
eBook Packages: Springer Book Archive